ZolmitriptanZolmitriptan
MedChemExpress (MCE)
HY-B0229
139264-17-8
BW-311C90
311C90
99.98%
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Room temperature in continental US
may vary elsewhere.
Zolmitriptan (BW-311C90
311C90) is a 5-HT1B/1D receptor partial agonist with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine.
Zolmitriptan (311C90) exhibits higher affinity to 5-HT than sumatriptan (pKA=6.63±0.04 and 6.16±0.03, respectively). 311C90 displays high affinity at human recombinant 5-HT1D and 5-HT1B receptors in transfected CHO-K1 cell membranes (pIC50 values=9.16±0.12 and 8.32±0.09, respectively) [1].
"Zolmitriptan (311C90
3-30 μg/kg, i.v.) causes a dose-dependent inhibition of [125I]-albumin extravasation within the ipsilateral dura mater. Zolmitriptan also produces dose-dependent falls in cranial vascular conductance (32.3% at 30 μg/kg)[1].Zolmitriptan is an anti-migraine agent with action at 5-HT1B/D receptors. Zolmitriptan is an effective and behaviorally specific anti-aggressive agent in situations that engender moderate and alcohol-heightened levels of aggression. Zolmitriptan (1-30 mg/kg, i.p.) exerts behaviorally specific anti-aggressive effects in mice[3]."
5-HT1B Receptor 5.01 nM (Ki) 5-HT1D Receptor 0.63 nM (Ki) 5-HT1F Receptor 63.09 nM (Ki)
| | | |
| | | | | |
[1]. G R Martin, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997 May
121(2):157-64. [Content Brief]
[2]. Katherine C Murray, et al. Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol. 2011 Aug
106(2):925-43. [Content Brief]